Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin αvβ3-positive tumors: A first-in-human study

Authors: Huimin Sui, Feng Guo, Hongfei Liu, Rongxi Wang, Linlin Li, Jiarou Wang, Chenhao Jia, Jialin Xiang, Yingkui Liang, Xiaohong Chen, Zhaohui Zhu, Fan Wang

Source: Acta Pharmaceutica Sinica B, Vol 15, Iss 2, Pp 669-680 (2025)

Subject Terms: 177Lu-AB-3PRGD2, Integrin αvβ3, Targeted radionuclide therapy, First-in-human study, Pharmacokinetics, Dosimetry, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2211383524004131; https://doaj.org/toc/2211-3835

Access URL: https://doaj.org/article/6d105e7845164ce4ae2c44beab87299e

Development of an extemporaneous preparation formulation using a simple and non-solubilizing matrix for first in human clinical study

Authors: Chiang, Cheng W. ^{a, 1}, Tang, Shijia ^{a, 1}, Boonstra, Jasper Martijn ^b, van Tilburg, Leon Pascal ^c, Liu, Jia ^a, Chiang, Po-Chang ^a, Rich, Sharyl ^{a, 2}, Wu, Newton ^d, Nguyen, Huy Q. ^d, Zhang, Wei ^{a, ⁎}, Hou, Hao Helen ^a, Leung, Dennis H. ^a

Source: In International Journal of Pharmaceutics 25 March 2024 653

Systemic administration of the antisense oligonucleotide NS‐089/NCNP‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial

Authors: Takami Ishizuka, Hirofumi Komaki, Yasuko Asahina, Harumasa Nakamura, Norio Motohashi, Eri Takeshita, Yuko Shimizu‐Motohashi, Akihiko Ishiyama, Chihiro Yonee, Shinsuke Maruyama, Eisuke Hida, Yoshitsugu Aoki

Source: Neuropsychopharmacology Reports, Vol 43, Iss 2, Pp 277-286 (2023)

Subject Terms: antisense oligonucleotide, DMD, Duchenne muscular dystrophy, exon 44, exon‐skipping, first‐in‐human study, Therapeutics. Pharmacology, RM1-950, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571

File Description: electronic resource

Relation: https://doaj.org/toc/2574-173X

Access URL: https://doaj.org/article/ee15b39e2405482aa4a970d87a49bf53

Scalp angiosarcoma treated with linear accelerator-based boron neutron capture therapy: A report of two patients

Authors: Hiroshi Igaki, Naoya Murakami, Satoshi Nakamura, Naoya Yamazaki, Tairo Kashihara, Akira Takahashi, Kenjiro Namikawa, Mihiro Takemori, Hiroyuki Okamoto, Kotaro Iijima, Takahito Chiba, Hiroki Nakayama, Ayaka Takahashi, Tomoya Kaneda, Kana Takahashi, Koji Inaba, Kae Okuma, Yuko Nakayama, Kazuaki Shimada, Hitoshi Nakagama, Jun Itami

Source: Clinical and Translational Radiation Oncology, Vol 33, Iss , Pp 128-133 (2022)

Subject Terms: Boron neutron capture therapy (BNCT), Linear accelerator-based BNCT system, Solid-state Li target, First-in-human study, Scalp-angiosarcoma, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S240563082200009X; https://doaj.org/toc/2405-6308

Access URL: https://doaj.org/article/d1594e222ff5484c9e8c0d168c93f61c

Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19

Authors: Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh Tripathi, Joseph M. Reardon, John Cafardi, Galia Rahav, Yoseph Caraco, Jihad Slim, Fadi Al Akhrass, Mengjia Yu, Yiran Hu, Rosa De Abreu Ferreira, Negar N. Alami

Source: Pharmacology Research & Perspectives, Vol 11, Iss 1, Pp n/a-n/a (2023)

Subject Terms: ABBV‐47D11, COVID‐19, first‐in‐human study, monoclonal antibodies, SARS‐CoV‐2, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://doaj.org/toc/2052-1707

Access URL: https://doaj.org/article/1ec46728fbc04f62a659f561489d4b07

Novel and emerging therapies for B cell lymphoma

Authors: Sabarish Ayyappan, Kami Maddocks

Source: Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-13 (2019)

Subject Terms: Lymphoma, First in human study, Immunotherapy, Cellular therapy, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s13045-019-0752-3; https://doaj.org/toc/1756-8722

Access URL: https://doaj.org/article/d34d7d92c7c546b7aaa7c20f462b364d

Safety, Tolerability, and Serum/Tear Pharmacokinetics of Human Recombinant Epidermal Growth Factor Eyedrops in Healthy Subjects

Authors: Hyounggyoon Yoo, Seonghae Yoon, In-Jin Jang, Kyung-Sang Yu, Joon Young Hyon, Jungi Hwang, Inyoung Hwang, Jung Sunwoo, Jae-Yong Chung

Source: Pharmaceuticals, Vol 15, Iss 11, p 1312 (2022)

Subject Terms: dry eye disease, epidermal growth factor, first-in-human study, pharmacokinetics, Medicine, Pharmacy and materia medica, RS1-441

File Description: electronic resource

Relation: https://www.mdpi.com/1424-8247/15/11/1312; https://doaj.org/toc/1424-8247

Access URL: https://doaj.org/article/eebaae5c84d44d0885c8e466f134bc51

First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [18F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas

Authors: Hiroyuki Fujimoto, Naotaka Fujita, Keita Hamamatsu, Takaaki Murakami, Yuji Nakamoto, Tsuneo Saga, Takayoshi Ishimori, Yoichi Shimizu, Hiroyuki Watanabe, Kohei Sano, Norio Harada, Hiroshi Nakamura, Kentaro Toyoda, Hiroyuki Kimura, Shunsaku Nakagawa, Mitsuharu Hirai, Atsushi Murakami, Masahiro Ono, Kaori Togashi, Hideo Saji, Nobuya Inagaki

Source: Frontiers in Endocrinology, Vol 12 (2021)

Subject Terms: β-cell imaging, exendin-4, glucagon-like peptide-1 receptor (GLP-1R), PET, first-in-human study, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fendo.2021.717101/full; https://doaj.org/toc/1664-2392

Access URL: https://doaj.org/article/d3b5de91dba247f7b39b785890233ef5

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects

Authors: Sidharta PN, Melchior M, Kankam MK, Dingemanse J

Source: Drug Design, Development and Therapy, Vol Volume 13, Pp 949-964 (2019)

Subject Terms: First-in-human study, endothelin, endothelin receptor antagonist, aprocitentan, pharmacokinetics, pharmacodynamics, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.dovepress.com/single--and-multiple-dose-tolerability-safety-pharmacokinetics-and-pha-peer-reviewed-article-DDDT; https://doaj.org/toc/1177-8881

Access URL: https://doaj.org/article/e43242bd80c04af9a0ce15ee90d8ca90

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.